Frailty in people living with HIV aged 70 and over: feasibility of screening for frailty, prevalence, risk factors and impact on the occurrence of adverse health events FRESH-PEF73421-en Mariem RAHO Frailty in people living with HIV aged 70 and over: feasibility of screening for frailty, prevalence, risk factors and impact on the occurrence of adverse health events ANRS EP66 SEPTAVIH FRESH-PEF73421-en 73421 FRESH-PEF73421 Laurence SLAMA Hubert BLAIN Clotilde ALLAVENA Laurence MEYER Mariem RAHO-MOUSSA AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) Epidemiology France Portal (PEF) AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) GILEAD SCIENCES MSD FRANCE VIIV HEALTHCARE SAS null Laurence;SLAMA Hubert;BLAIN Alain;MAKINSON Clotilde;ALLAVENA Laurence;MEYER Mariem;RAHO-MOUSSA HIV infection frailty geriatrics Geriatrics Infectious disease medicine Internal medicine Human immunodeficiency virus disease without mention of tuberculosis or malaria Behavioral determinants: Addiction Socio-demographic and economic determinants Healthcare system determinants: Use of care Behavioral determinants Healthcare system determinants To evaluate the prevalence of frailty according to Fried's criteria in people living with HIV aged 70 and over Secondary objectives: To study and describe frailty in PLHIV aged 70 and over according to different indexes: Fried, Cumulative Deficit Index, HAS score, VACS index Study the association between frailty and various parameters specific to HIV infection and other non-specific parameters Identify factors associated with frailty at M0 and with progression or regression of frailty during 12 months of follow-up Study the occurrence of adverse health events during the 12 months of follow-up (falls, emergency room visits, hospitalisations, institutionalisation, loss of an iADL point, death) Evaluate the prevalence of sarcopenia and osteoporosis Describe the population (socio-demographic characteristics, socio-economic level, HIV infection and treatment history, comorbidities, polymedication, mental health, quality of life, etc.) Study inflammatory and immunosenescence markers at M0 null France Individuals Patients population Male Female Other Aged (65 to 79 years) Aged, 80 and over (80 years and more) Clinical data Participant-reported health data Biological data Paraclinical data (non-biological) : Imaging ATC for drugs ICD10 for cause of death Risk-based monitoring (on-site and remote) planned data management procedures Other Through organizations (health services or institutions schools businesses etc.) Other Observational Study Observational Study 512 Unknown To be defined